|
MechanismImmunoglobulin modulators |
|
|
|
Inactive Indication- |
Drug Highest PhaseClinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
MechanismImmunostimulants |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
A One Arm, Open Label,Multi - Center Phase II Study to Evaluate the Safety and Efficacy of IVIG in the Treatment of Various Metastatic Solid Tumors for Which There is no Better Alternate Treatment
The purpose of this study is to evaluate the safety and efficacy of IVIG in the treatment of metastatic cancer of the prostate, colon and melanoma.
100 Clinical Results associated with Gammacan International, Inc.
0 Patents (Medical) associated with Gammacan International, Inc.
100 Deals associated with Gammacan International, Inc.
100 Translational Medicine associated with Gammacan International, Inc.